Clinical Trial Update: Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis [Phase 3]

View source ↗

Summary

Phase 3 study of DE-114 ophthalmic solution for allergic conjunctivitis has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis

Drugs mentioned

• DE-114 Ophthalmic Solution

Snippet

Sponsor: Santen Pharmaceutical Co., Ltd. | Conditions: Allergic Conjunctivitis | Phase 3 | Status: COMPLETED | Results posted: 2014-11-05